Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 19/20 | 0.70 |
| ▸ | PSEN2 | P49810 | 19/20 | 0.70 |
| ▸ | APH1B | Q8WW43 | 19/20 | 0.70 |
| ▸ | NCSTN | Q92542 | 19/20 | 0.70 |
| ▸ | APH1A | Q96BI3 | 19/20 | 0.70 |
| ▸ | PSENEN | Q9NZ42 | 19/20 | 0.70 |
| ▸ | GSAP | A4D1B5 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7346301 | 1.00 | PSEN1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4987183 | 0.88 | PSEN1 (0.76) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4990447 | 0.86 | PSEN1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4989917 | 0.86 | PSEN1 (0.70) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4411858 | 0.83 | PSEN1 (0.73) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7337192 | 0.82 | PSEN1 (1.00) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4992948 | 0.81 | PSEN1 (0.69) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7609721 | 0.81 | PSEN1 (0.69) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4990943 | 0.80 | PSEN1 (0.86) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL7689272 | 0.79 | PSEN1 (0.68) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6432944-B1 | ARYLACETAMIDOALANYL DERIVATIVES OF BENZODIAZEPINONES ARE USEFUL FOR INHIBITION OF EXTRACELLULAR DEPOSITION OF BETA-AMYLOID PEPTIDE, THUS TREATS AMYLOIDOSIS, ALZHEIMER'S DISEASE AND DOWN'S SYNDROME | BRISTOL-MYERS SQUIBB COMPANY | 2002-08-13 | — | — | US | disclosed |
| US-20020022621-A1 | Benzodiazepinone beta -amyloid inhibitors: arylacetamidoalanyl derivatives | BRISTOL-MYERS SQUIBB COMPANY | 2002-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022621-A1 | Benzodiazepinone beta -amyloid inhibitors: arylacetamidoalanyl derivatives | APP, BACE1, PSEN1 | PSEN1 3/4885PSEN2 5/4885APH1B 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.